Mankind Pharma profit jumps 30% on chronic therapy demand in Q4

Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chronic therapies and consumer healthcare products. The company's domestic formulations business is showing a revival. Improved sales execution and the successful integration of Bharat Serums and Vaccines contributed to this positive performance.